Nuvalent Inc (NUVL) vs Entrada Therapeutics, Inc. (TRDA)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NUVL | TRDA | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Size band | MID | SMALL |
| Listing | Nasdaq GM | Nasdaq GM |
| Country | United States | United States |
| Theme | oncology | rare-disease |
| Price and returns | ||
| Last close | $123.96 | $4.75 |
| Return · 1 week | 0.00% | −1.45% |
| Return · 1 month | 0.00% | −23.63% |
| Return · 3 months | 0.00% | −18.52% |
| Return · year to date | +22.93% | −52.74% |
| Return · 1 year | +26.87% | −35.02% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −0.02% | −71.12% |
| 52-week high | $123.99 | $16.45 |
| 52-week low | $87.30 | $4.11 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $9.79B | $184.95M |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $149.69M | $1.40M |
| Employees | 234 | 152 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | — | 36.31× |
| Price to book | 8.33× | 0.68× |
| Enterprise value to EBITDA | — | n/a (negative enterprise value and EBITDA) |
| Enterprise value to revenue | — | n/a (negative enterprise value) |
| Earnings per share · trailing | -6.06 | -3.96 |
| Profitability | ||
| Operating margin | 0.00% | −5007.02% |
| Profit margin | — | −3537.73% |
| Return on equity | −41.19% | −54.10% |
| Return on assets | −22.51% | −29.20% |
| Growth | ||
| Revenue growth | — | −53.90% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 20.80 |
| Current ratio | 16.14 | 10.89 |
| Dividend yield | — | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | — | 26.74 |
| ADX · 14 | — | 33.43 |
| 50-day average | — | $6.58 |
| 200-day average | — | $9.05 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | — | 10.20% |
The full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysisThe full TRDA analysis
Everything this table leaves out for Entrada Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TRDA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TRDA analysis